Brokerages predict that Heska Corp (NASDAQ:HSKA) will post sales of $41.14 million for the current quarter, according to Zacks. Two analysts have made estimates for Heska’s earnings, with estimates ranging from $40.91 million to $41.38 million. Heska posted sales of $39.54 million during the same quarter last year, which would indicate a positive year over year growth rate of 4%. The company is expected to report its next earnings report on Tuesday, February 27th.

On average, analysts expect that Heska will report full year sales of $41.14 million for the current financial year, with estimates ranging from $137.06 million to $138.00 million. For the next financial year, analysts expect that the business will report sales of $154.17 million per share, with estimates ranging from $152.90 million to $155.21 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that cover Heska.

Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03. The business had revenue of $31.40 million for the quarter, compared to analyst estimates of $36.10 million. Heska had a return on equity of 15.35% and a net margin of 10.67%. The business’s revenue for the quarter was down 6.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.45 earnings per share.

A number of analysts recently commented on HSKA shares. Canaccord Genuity started coverage on Heska in a research note on Thursday, October 5th. They set a “buy” rating and a $115.00 price objective on the stock. Benchmark reaffirmed a “buy” rating and set a $120.00 price objective (up previously from $106.00) on shares of Heska in a research note on Wednesday, August 9th. B. Riley reaffirmed a “hold” rating and set a $96.50 price objective on shares of Heska in a research note on Friday, October 27th. Zacks Investment Research lowered Heska from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, BidaskClub lowered Heska from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $113.30.

Shares of Heska (NASDAQ:HSKA) opened at $85.93 on Tuesday. The company has a market capitalization of $625.25, a price-to-earnings ratio of 45.19, a P/E/G ratio of 2.30 and a beta of 0.75. Heska has a 52 week low of $65.33 and a 52 week high of $115.00.

In other Heska news, insider Michael J. Mcginley sold 7,826 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total value of $681,957.64. Following the sale, the insider now directly owns 106,771 shares of the company’s stock, valued at approximately $9,304,024.94. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 14.70% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the business. State of Wisconsin Investment Board acquired a new stake in Heska in the 2nd quarter worth about $510,000. Neuberger Berman Group LLC raised its holdings in shares of Heska by 1.0% in the 2nd quarter. Neuberger Berman Group LLC now owns 449,574 shares of the medical research company’s stock worth $45,888,000 after purchasing an additional 4,329 shares during the period. Vanguard Group Inc. raised its holdings in shares of Heska by 31.7% in the 2nd quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock worth $47,141,000 after purchasing an additional 111,232 shares during the period. Marshall Wace North America L.P. purchased a new position in shares of Heska in the 2nd quarter worth about $4,847,000. Finally, Northern Trust Corp raised its holdings in shares of Heska by 5.7% in the 2nd quarter. Northern Trust Corp now owns 120,060 shares of the medical research company’s stock worth $12,255,000 after purchasing an additional 6,517 shares during the period. 81.98% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/05/analysts-anticipate-heska-corp-hska-will-announce-quarterly-sales-of-41-14-million.html.

About Heska

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with MarketBeat.com's FREE daily email newsletter.